• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cardinal Health OKs $1B share buyback after taking a hit on tightened guidance

Cardinal Health OKs $1B share buyback after taking a hit on tightened guidance

May 5, 2016 By Brad Perriello

Cardinal HealthCardinal Health (NYSE:CAH) said today that its board approved a $1 billion share buyback plan, after the company’s stock price took a hit last week after it tightened its earnings outlook for the rest of the year.

Dublin, Ohio-based Cardinal said the share repurchasing program, which is slated to end Dec. 31, 2019, is in addition to the $393 million still remaining from a prior buyback plan. Cardinal Health’s board also OK’d a 16% boost to its quarterly dividend to 44.89¢ per share.

CAH stock fell more than -9% April 28 after the company’s fiscal 3rd-quarter results prompted it to tighten its full-year guidance. Cardinal Health posted profits of $386 million, or $1.17 per share, on sales of $30.7 billion for the quarter, amounting to a 5.8% bottom-line gain on sales growth of 20.9% compared with Q3 2015.

Adjusted to exclude 1-time items, earnings per share were $1.43, a full dime ahead of Wall Street’s consensus forecast. Still, CAH shares closed down -9.3% at $78.51 apiece April 28, the day of the earnings release as investors reacted to the updated outlook. CFO Michael Kaufmann told analysts that Cardinal Health now expects to report adjusted EPS of $5.17 to $5.27 for fiscal 2016, implying 4th-quarter guidance of $1.07 to $1.17.

“We had a strong financial and operational performance in our fiscal 3rd quarter. At the same time, we continued to enhance and grow enterprise-wide service and product lines, which are important to our customers and address some of healthcare’s most difficult challenges,” chairman & CEO George Barrett said in prepared remarks. “We delivered double-digit growth in revenue and profit in both our pharmaceutical and medical reporting segments and had very solid performance across our lines of business.”

The buyback announcement had the desired effect, as CAH shares were up 1.6% to $78.72 today in mid-morning trading.

Cardinal Health said its medical business saw profits rise 25.5% to $128 million on sales growth of 10.7% to $3.1 billion, “due to the net contribution from acquisitions as well as solid growth from existing businesses.” The company closed its $1.94 billion buyout of Johnson & Johnson‘s (NYSE:JNJ)’s Cordis stent-making arm last October.

Filed Under: MassDevice Earnings Roundup, Wall Street Beat Tagged With: Cardinal Health

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy